Methergin (Methylergometrine Maleate)

Methylergometrine maleate acts as a partial agonist at serotonin 5‑HT2, alpha‑adrenergic and dopaminergic receptors in uterine smooth muscle. This activation raises intracellular calcium, producing strong uterine contraction and vasoconstriction that help limit bleeding.

The specific dose of Methergin is determined by the prescribing clinician based on the patient’s condition, route of administration, and clinical guidelines. Healthcare professionals set the appropriate amount and frequency for each individual case.

Methergin is intended for use after delivery to control postpartum bleeding. Its safety profile for use during pregnancy has not been established, and it is generally not recommended for that purpose. Caution is advised when breastfeeding, and the prescriber should evaluate the risk‑benefit ratio.

To order Methergin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Both Methergin and oxytocin are uterotonics, but they differ in mechanism and side‑effect profile. Oxytocin works via oxytocin receptors and is often first‑line for uterine contraction, while Methergin acts on serotonin, alpha‑adrenergic and dopaminergic receptors, providing a stronger vasoconstrictive effect. Methergin may be used when oxytocin alone is insufficient or contraindicated.

Methergin should be stored at 2‑8 °C, protected from light, and kept in its original packaging to avoid moisture. It must not be frozen or shaken vigorously. Before use, inspect the solution for particulate matter or discoloration and discard if any abnormalities are observed.

Methergin is administered by a healthcare professional via intramuscular, intravenous, or subcutaneous injection. The route and injection site are selected according to clinical need and the prescribing information, with careful monitoring of the patient’s vital signs during and after administration.

Serious risks include severe hypertension or hypertensive crisis, myocardial ischemia or infarction, pulmonary edema, and severe allergic reactions such as anaphylaxis. Immediate medical attention is required if any of these events occur, and patients should be monitored closely for cardiovascular changes.

Methergin should be avoided in patients with uncontrolled hypertension, known hypersensitivity to ergot alkaloids, severe coronary artery disease, or those receiving other potent vasoconstrictors. It is also contraindicated in individuals with a history of severe peripheral vascular disease or in whom uterine rupture risk is high.